European Biotech Acquisition Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and European Biotech are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days European Biotech Acquisition has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, European Biotech is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
European |
European Biotech Relative Risk vs. Return Landscape
If you would invest (100.00) in European Biotech Acquisition on October 14, 2025 and sell it today you would earn a total of 100.00 from holding European Biotech Acquisition or generate -100.0% return on investment over 90 days. European Biotech Acquisition is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than European, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
European Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for European Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as European Biotech Acquisition, and traders can use it to determine the average amount a European Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EBAC |
Based on monthly moving average European Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of European Biotech by adding European Biotech to a well-diversified portfolio.
European Biotech Fundamentals Growth
European Stock prices reflect investors' perceptions of the future prospects and financial health of European Biotech, and European Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on European Stock performance.
| Current Valuation | 164.04 M | |||
| Shares Outstanding | 13.21 M | |||
| Price To Earning | 66.40 X | |||
| Price To Book | 1.34 X | |||
| EBITDA | 342.89 K | |||
| Cash And Equivalents | 308.1 K | |||
| Cash Per Share | 0.02 X | |||
| Book Value Per Share | (0.37) X | |||
| Cash Flow From Operations | (514.79 K) | |||
| Earnings Per Share | 0.02 X | |||
| Total Asset | 129.75 M | |||
Things to note about European Biotech Acq performance evaluation
Checking the ongoing alerts about European Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for European Biotech Acq help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| European Biotech Acq is not yet fully synchronised with the market data | |
| European Biotech Acq has some characteristics of a very speculative penny stock | |
| European Biotech Acq has a very high chance of going through financial distress in the upcoming years | |
| European Biotech Acquisition currently holds about 308.1 K in cash with (514.79 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies |
- Analyzing European Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether European Biotech's stock is overvalued or undervalued compared to its peers.
- Examining European Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating European Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of European Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of European Biotech's stock. These opinions can provide insight into European Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in European Stock
If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |